VRDN-003 + Placebo

Phase 3Active

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Thyroid Eye Disease (TED)

Conditions

Thyroid Eye Disease (TED)

Trial Timeline

Feb 3, 2025 → Oct 1, 2026

NCT ID

NCT06812325

About VRDN-003 + Placebo

VRDN-003 + Placebo is a phase 3 stage product being developed by Viridian Therapeutics for Thyroid Eye Disease (TED). The current trial status is active. This product is registered under clinical trial identifier NCT06812325. Target conditions include Thyroid Eye Disease (TED).

What happened to similar drugs?

20 of 20 similar drugs in Thyroid Eye Disease (TED) were approved

Approved (20) Terminated (4) Active (0)

✅LenvatinibEisaiApproved

✅Cinacalcet HClKyowa KirinApproved

✅Growth hormone + Growth hormone treatment and pubertyEli LillyApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06812325	Phase 3	Active	Feb 3, 2025	Oct 1, 2026	Thyroid Eye Disease (TED)
NCT06625411	Phase 3	Active	Aug 27, 2024	Nov 15, 2026	Thyroid Eye Disease
NCT06625398	Phase 3	Active	Aug 27, 2024	Dec 15, 2026	Thyroid Eye Disease

Competing Products

20 competing products in Thyroid Eye Disease (TED)

See all competitors

Product	Company	Stage	Hype Score
MBX 2109	MBX Biosciences	Phase 2	29
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection	MBX Biosciences	Phase 2	33
PCO371 + Placebo	Chugai Pharmaceutical	Phase 1	21
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib + Placebo + Lenvatinib	Eisai	Phase 3	40
Irofulven + capecitabine	Eisai	Phase 2	35
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Approved	43
Lenvatinib	Eisai	Pre-clinical	26
Bexarotene	Eisai	Phase 1	29
Lenvatinib + Lenvatinib matching placebo	Eisai	Phase 2	35
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
E7080 capsule	Eisai	Phase 2	35
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)	Eisai	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27